AbbVie Scores HCV First Under UK’s Early Access Scheme
Executive Summary
AbbVie’s investigational hepatitis C treatment has become the latest therapy to get the green light under the UK’s early access to medicines scheme. The scheme enables patients to access the treatment ahead of it receiving an EU marketing authorization.
You may also be interested in...
AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU
AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe this week – but AbbVie's drug is the one to watch as analysts have dubbed it a potential blockbuster.
Imminent EU CHMP Opinions: Kidney And Breast Cancer, Mastocytosis, MS, Emphysema & Hepatitis C
Among products that are due for a go/no-go recommendation by the European Medicines Agency this week are new drugs for conditions such as cancer, multiple sclerosis, mastocytosis, HIV and hepatitis C.
Orphan Drugs Dominate EU Fast-Track Request Decisions In July
The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for four potential new orphan treatments.